Patients with deadly TB released in South Africa

Image
AP London
Last Updated : Jan 17 2014 | 6:40 AM IST
The spread of a virtually untreatable form of tuberculosis in South Africa is being fuelled by the release of infected patients into the general community, according to a new study.
Scientists tracked 107 patients with extensively drug-resistant TB, also known as XDR-TB in three South African provinces between 2008 and 2012. Despite most patients being treated with about eight TB drugs, 78 died.
More than 40 others were released from hospitals without further monitoring. TB is an infectious bacterial infection that usually affects the lungs and is often spread by coughing and sneezing.
In one case, DNA testing confirmed a discharged patient passed on the deadly strain to his brother; both eventually died without being admitted to a hospital.
Researchers said releasing patients with the lethal TB strain was happening on a widespread level in South Africa because there were few available beds in TB hospitals or palliative care facilities.
"These patients can survive for months or even years and are contributing to the community-based spread of XDR-TB," said Keertan Dheda of the University of Cape Town in South Africa, who led the study.
The research was published online today in the journal, Lancet. Dheda described the situation as alarming and called for modern sanatoriums to be built so patients could be treated away from society.
South Africa has the world's highest number of patients with XDR-TB and health officials warn other drug-resistant forms of the disease are spreading at an increasing rate, most notably in eastern and central Europe, China, India and Africa.
In an accompanying commentary, Max O'Donnell and Neil Schluger of the Albert Einstein College of Medicine in New York and the World Lung Foundation, described drug-resistant TB as an "out-of-control problem with potentially vast and devastating repercussions for global public health."
Globally, experts estimate only about one in five people with drug-resistant TB is diagnosed or treated.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 17 2014 | 6:40 AM IST

Next Story